Urtoxazumab

Urtoxazumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	E. coli Shiga-like toxin II B subunit
Identifiers
CAS Number	502496-16-4^N
ATC code	None
ChemSpider	none
Chemical data
Formula	C₆₄₁₄H₉₉₃₄N₁₇₁₈O₂₀₁₀S₄₀
Molar mass	144.6 kDa
^NY (what is this?) (verify)

Urtoxazumab is a humanized monoclonal antibody against diarrhoea caused by Escherichia coli, serotype O121. The drug is designed to bind to a toxin of this bacterium, so that it can be more easily broken down and eliminated from the body.^[1]^[2]

References

↑ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
↑ López, EL; Contrini, MM; Glatstein, E; González Ayala, S; Santoro, R; Allende, D; Ezcurra, G; Teplitz, E; et al. (2009). "Safety and Pharmacokinetics of Urtoxazumab, a Humanized Monoclonal Antibody Against Shiga-Like Toxin 2 in Healthy Adults and Pediatric STEC- Infected Patients". Antimicrobial Agents and Chemotherapy 54 (1): 239–243. doi:10.1128/AAC.00343-09. PMC 2798559. PMID 19822704.

Monoclonal antibodies for infectious disease and toxins

Fungal ("-fung-")

Human ("-fungu-")	Efungumab

Viral ("-v(i)[r]-")

Human ("-viru-")	Diridavumab Exbivirumab Foravirumab Libivirumab Rafivirumab Regavirumab Sevirumab Tuvirumab

Humanized ("-vizu-")	Felvizumab Motavizumab Palivizumab Suvizumab

Bacterial ("-ba(c)-")

Human ("-bacu-")	Nebacumab Panobacumab Raxibacumab

Mouse ("-baco-")	Edobacomab

Chimeric ("-baxi-")	Pagibaximab

Humanized ("-bazu-")	Tefibazumab^†

Toxin ("-tox(a)-")

Human ("-toxu-")	Actoxumab Bezlotoxumab

Chimeric ("-toxaxi-")	Obiltoxaximab

Humanized ("-toxazu-")	Urtoxazumab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Monday, February 15, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.